Myrtelle to Present Positive 6-month Post-Treatment Data in Its First- in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the National Tay-Sachs and Allied Diseases Annual Family Conference
Wakefield, Mass., Wednesday, May 31, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Article Date
May 31, 2023
This article is featured on another website.
Go to article
August 26, 2026
Asia’s Shifting Regulatory Map: What Sponsors Need to Know Before Choosing a Trial Location
Part 3 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…
August 26, 2026
Asia’s Shifting Regulatory Map: What Sponsors Need to Know Before Choosing a Trial Location
Part 3 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…
July 15, 2026
Glioblastoma Clinical Trials – Where Progress is Actually Happening in Glioma Research
Where Glioma Research Is Actually Moving Forward Glioblastoma (GBM) is the most common and most…
July 15, 2026
Glioblastoma Clinical Trials – Where Progress is Actually Happening in Glioma Research
Where Glioma Research Is Actually Moving Forward Glioblastoma (GBM) is the most common and most…